Phesi Analysis Shows Breast Cancer Was the Most Extensively Studied Disease Area in 2021
Data also show COVID-19 to be second most studied disease area, and further highlight patient enrollment challenges.
Phesi Inc. today released the results of its global analysis of all clinical trials conducted in 2021. The data show that breast cancer was the most studied disease area, followed by COVID-19. Overall, oncology dominated the top five, which also included non-small cell lung cancer, solid tumors and multiple myeloma.
Within breast cancer clinical development 25,000 investigator sites have been solely dedicated to recruiting patients since 2017; this trend was not impacted by COVID-19; this includes pharma and academic studies and the same investigator sites involved in multiple trials. This means an average of 5,000-7,000 people are continually working on breast cancer clinical trials, with Phesi’s model showing this is likely to continue.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
